IPSEN : Appointment of Claude Bertrand as Executive Vice President, Chief Scientific Officer of Ipsen

Regulatory News:

Jacques-Pierre Moreau is appointed Chief Scientific Advisor to the Executive Committee

Ipsen (Euronext: FR0010259150; IPN) today announced that Claude Bertrand will join Ipsen, as of November 2^nd, as Executive Vice President, Chief Scientific Officer and Member of the Executive Committee of the Group.

C. Bertrand will lead the Discovery and Innovation operations at Les Ulis (France), Milford (United States) and Barcelona (Spain) and will further strengthen Ipsen's commitment to research and maintain the tradition of excellence that has presided over Discovery and Innovation activities. He shall operate from Paris/Boulogne (France) and Milford (United States) sites. Former Senior Vice President at AstraZeneca R&D he had a distinguished international research career that spanned over 20 years in the drug industry starting with Ciba-Geigy (now Novartis) then Roche Bioscience (part of F. Hoffmann-La Roche Ltd) and Pfizer Global R&D.

Claude Bertrand will succeed Jacques-Pierre Moreau (61 years old) who will continue to contribute to Ipsen's future in an advisory position (as Chief Scientific Advisor) to the Executive Committee on scientific, medical and technical matters. In this non-executive position, he will perform strategic missions and participate to non-operational oversight of spin-offs, venture fundings and academic alliances.

Jean-Luc Bélingard, Chairman and CEO of Ipsen said: ?In the changing environment of the pharmaceutical industry, it is more than ever imperative for Ipsen to remain at the forefront of drug discovery with first-in-class products as well as creative life cycle management programs that foster closer links with health care providers and patients. We have to continue to creatively enrich our innovation pipeline, and at the same time bring to fruition as quickly as possible our current projects as they result from our long-term dedication to R&D, integral part of Ipsen's DNA. With C. Bertrand at the helm of D&I and with the benefit of J-P. Moreau long-term experience and knowledge of the life sciences as applied to therapeutic R&D, I am convinced that our future as an innovation company is in good hands.?

Dr. Claude Bertrand (47-years old) graduated in pharmacy (Pharm.D.) from Strasbourg University (France) and then obtained his PhD in Strasbourg (France) with research in the fields of immuno-pharmacology and neurogenic inflammation. After a 2-year post-doctoral appointment at University of California, San Francisco with Prof. Jay A. Nadel, he joined the allergy and asthma unit at Ciba-Geigy (later Novartis) in Basel (Switzerland). In 1996, he moved to the Inflammatory disease Unit at Roche Bioscience in Palo Alto, California where he became head of the in vivo pharmacology group and was responsible for supporting projects in arthritis and respiratory diseases. During that time C. Bertrand also co-ordinated chemokine research for Roche Global. In 1999, he was recruited as Director of Pharmacology for Inflammation, GI and Pain at the Fresnes (France) R&D site of Parke-Davies, which later became part of Pfizer. In 2004, Dr. Bertrand joined AstraZeneca as Vice-President Discovery for Respiratory & Inflammation Research at Alderley Park and in 2005 was appointed Global Vice President for Respiratory & Inflammation Research Area overseeing research activities and 700 employees at three sites in the UK and Sweden. In June 2009, he moved to the Development organisation at Astra Zeneca as Senior Vice President, Launched and Established brands.

About Ipsen

Ipsen (Paris:IPN) is an innovation-driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Its development strategy is based on a combination of specialty medicine, which is Ipsen's growth driver, in targeted therapeutic areas (oncology, endocrinology, neurology and haematology), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 800 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partnerships. In 2008, Research and Development expenditure was about €183 million, close to 19% of consolidated sales, which amounted to €971 million while total revenues exceeded €1 billion. Ipsen's shares are traded on Segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150). Ipsen's shares are eligible to the ?Service de Règlement Différé? (?SRD?) and the Group is part of the SBF 120 index. For more information on Ipsen, visit our website at www.ipsen.com.

Ipsen
Media
Didier Véron
Director, Public Affairs and Corporate Communications
Tel.: [phone]
Fax: [phone]
E-mail:[e-mail]
or
Financial Community
David Schilansky
Investor Relations and Financial Officer
Tel.: [phone]
Fax: [phone]
E-mail: [e-mail]
or
Pierre Kemula
Investor Relations Manager
Tel.: [phone]
Fax: [phone]
E-mail: [e-mail]